Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register

China's Biotech Out-Licensing Boom: An In-Licensing Opportunity for Emerging Markets

Mitul Agarwal
Written by Mitul Agarwal · B.Pharm, MBA
Founder & Head of Business Development · 25+ years in international pharmaceutical BD&L
Published 21 November 2026
China's Biotech Out-Licensing Boom: An In-Licensing Opportunity for Emerging Markets

By the PharmaTradz BD Team. Published November 2026.

In short: Chinese biotechs are now the single biggest source of new drugs licensed by large pharmaceutical companies: about half of major in-licensing deals in 2026 involved assets from China. Big pharma usually takes rights for the US, Europe and other major markets, which often leaves rights for Southeast Asia, the Middle East, Latin America and Africa with the Chinese developer. For regional pharma companies, that creates a real in-licensing opportunity, provided they check data acceptability and manufacturing readiness first.

Five years ago, licensing a new drug from China was unusual for a global pharma company. In 2026 it is routine. The shift is one of the biggest structural changes in pharma business development this decade, and its effects reach well beyond the US and Europe.

The numbers

  • Assets from China accounted for 51% of major in-licensing deals with upfront payments of at least US$50 million through September 2026, up from 39% in 2025 and 18% in 2023, according to J.P. Morgan and DealForma data cited by GeneOnline. Chinese companies took 65% of the upfront capital in that category.
  • In the first half of 2026 alone, Chinese companies signed 85 outbound licensing deals with a combined headline value of about US$100 billion, although upfront payments were under 6% of that total (Life Science Daily deal tracker).
  • The largest 2026 deal so far carried a US$1.2 billion upfront payment and up to US$18.5 billion in total value.

Headline values include milestones that may never be paid, so the upfront figures are the better guide to real money changing hands.

Why big pharma is buying from China

  1. Patent cliffs. Large companies face major losses of exclusivity before 2030 and need late-stage assets quickly.
  2. Speed and cost. Chinese biotechs have moved quickly from discovery to clinical proof of concept at lower cost, especially in oncology, immunology and obesity.
  3. Fast-follower and next-generation formats. Bispecific antibodies, antibody-drug conjugates and oral small molecules have attracted the largest deals.

The policy risk

US scrutiny of China-linked biotechnology is rising. The BIOSECURE Act restricts certain federally funded work with named "biotechnology companies of concern", and proposals have been made to review licensing deals with Chinese companies. Reports in September 2026 suggested draft rules would leave most licensing deals intact while excluding sensitive areas, and the broader review bill has not been enacted. Deal-makers are adding protections, such as moving manufacturing outside China for US supply, rather than walking away.

The opportunity for regional companies

Large global licensees typically take rights for the US, Europe, Japan and sometimes worldwide outside China. But many deals are territory-specific, and rights for emerging markets are frequently retained by the Chinese developer, which may have little presence in those regions. That opens doors for pharma companies in Southeast Asia, the Gulf, North Africa, Latin America and sub-Saharan Africa to in-license innovative products for their own markets.

Before signing, regional companies should check:

  • Data acceptability. Will your regulator accept data from trials run mainly in China? Some require global or regional data, or a bridging study.
  • Reference approvals. Many emerging-market regulators rely on approval by a stringent or reference authority. If the product is approved only in China, check whether your country accepts an NMPA approval or will wait for a US or EU decision.
  • Manufacturing and supply. Confirm GMP status, capacity reserved for your territory, and any supply risks from export or policy changes.
  • Rights clarity. Make sure the developer still holds your territory and that later global deals cannot override your licence.
  • Commercial terms. Upfront, milestones, royalties and minimum orders should reflect the size of your market.

Our view

We think China's rise as a source of innovation is permanent, not a cycle, and that policy friction will change deal structures rather than stop them. The most interesting consequence for the rest of the world is not the multi-billion-dollar headline deals but the territories they leave behind. Regional companies that once could only license old generics can now access genuinely new medicines, often with faster timelines than waiting for a global originator to launch in their markets.

The companies that benefit will be those that do the regulatory homework early: understanding what their regulator needs, which reference approvals count, and how to bridge data gaps. Those that treat Chinese in-licensing like buying a generic dossier will run into delays.

Related reading on PharmaTradz

The bottom line

China now supplies about half of big pharma's major licensing deals. The rights those deals leave behind are one of the best in-licensing opportunities emerging-market companies have had in years.

This article is general business information, not legal, regulatory or investment advice. Deal data come from third-party trackers and may differ between sources; check details before relying on them.


Frequently Asked Questions(FAQs)

How much of big pharma's licensing now comes from China?

About half. Assets from China made up 51% of major in-licensing deals with upfronts of at least US$50 million through September 2026, up from 18% in 2023, according to J.P. Morgan and DealForma data.

Why are large pharma companies licensing drugs from China?

To refill pipelines before patent cliffs, and because Chinese biotechs have reached clinical proof of concept quickly and at lower cost, especially in oncology, immunology and obesity.

Do US policies block licensing deals with Chinese companies?

Not broadly so far. The BIOSECURE Act restricts work with named companies of concern, and draft rules reported in 2026 would leave most licensing deals intact, though scrutiny is rising.

Can regional companies license Chinese innovative drugs for emerging markets?

Often yes, because global licensees usually take major-market rights and many emerging-market territories stay with the Chinese developer.

What should be checked before in-licensing a drug from China?

Whether your regulator accepts the trial data, which reference approvals it requires, GMP status and supply capacity, clear territorial rights, and commercial terms that suit your market size.

Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.

Category: Pharma Blogs

← Back to All Articles

 

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us